Provider Login
My Account
Become a Provider

Semax: Benefits, Handling, Side Effects, and Quality Standards

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.

What is Semax?

Semax is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH), modified for metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been used in Russian clinical practice for stroke rehabilitation since the 1990s. Semax retains ACTH(4-10)’s neurological signaling activity without the hormonal, corticosteroid-releasing activity of the parent molecule. It is not FDA-approved in the United States, where it is supplied strictly as a research compound.

Benefits and Uses

Available research on Semax spans several areas of interest, with the honest framing that the deepest evidence base comes from Russian clinical and preclinical research, and independent Western replication remains limited:

  • BDNF and neurotrophic signaling. The best-characterized mechanism; research has reported that Semax upregulates brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the hippocampus and other brain regions, along with nerve growth factor (NGF) expression.
  • Cognitive performance. Semax has been studied in Russian research for its effects on attention, learning, and memory in both animal models and human volunteers.
  • Neuroprotection and stroke research. Published Russian clinical research has examined Semax as an adjunct to standard stroke care, with reported effects on neurological outcomes and plasma BDNF levels.
  • Preliminary and hypothesis-stage research. A published hypothesis paper has proposed Semax as a candidate for further research in attention-deficit hyperactivity disorder, based on its BDNF and dopaminergic activity. This is a theoretical proposal, not an established clinical finding. No large-scale controlled trials have been conducted, and Semax is not approved for this or any indication in the United States.
The BDNF/neurotrophic mechanism is well documented across animal and human research. Broader cognitive and neuroprotective claims rest substantially on the Russian clinical research base, which has seen limited independent replication outside that research program.

How It Works

Semax’s primary studied mechanism is upregulation of BDNF and activation of its TrkB receptor, triggering downstream signaling cascades including MAPK/ERK and PI3K/Akt pathways associated with neuronal survival and synaptic plasticity. Because Semax derives from ACTH(4-10) but lacks the corticosteroid-releasing portion of the molecule, research indicates it acts on these neural pathways without triggering the hormonal cascade associated with full ACTH activity.

Dosage and Administration

No standardized dosing protocol exists for Semax outside of individual study designs, and any research protocol, route, or dose is determined solely by the licensed researcher or practitioner and their institution.

Semax has most frequently been studied via intranasal administration in its Russian clinical research history, which is the basis for its supply as a nasal formulation; subcutaneous administration has also been used in research settings. This reflects historical study design, not a recommended or current protocol.

For labs converting a professional’s own determined research dose into an accurate reconstitution volume, CellGenic’s calculator tool is open to any visitor, with no account required.

Side Effects and Safety

Semax is generally reported as well tolerated across its extensive Russian clinical-use history. Reported effects are mild, primarily nasal irritation with intranasal use. Long-term human safety data outside the Russian clinical research record remain limited. Researchers should establish baseline laboratory values before and during any protocol.

Quality & Verification Standards

Every CellGenic lot is manufactured under cGMP conditions and undergoes mycoplasma, sterility, identity, and potency testing prior to release. Certificates of Analysis are issued per batch and can be retrieved directly using your batch number.

Semax vs. N-Acetyl Semax

CellGenic supplies two related research formulations: standard Semax as a nasal spray and N-Acetyl Semax as a lyophilized vial for reconstitution. The acetyl modification on N-Acetyl Semax is studied for altering the peptide’s stability and clearance profile relative to standard Semax. Which form is relevant to a given research protocol depends on the study design and route being investigated.

Become a Verified Provider

Certificates of Analysis, batch documentation, and pricing are available exclusively to verified physicians, clinic operators, and researchers.

Become a Provider → A CellGenic specialist will follow up within one business day. Once your account is verified, full pricing and Certificates of Analysis unlock automatically.

References:

  1. PubMed: Semax peptide neuroprotection literature
  2. PubMed: Semax and ACTH fragment research
  3. FDA: Bulk drug substances used in compounding under Section 503A

FAQ

What is Semax?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, modified for metabolic stability. Research suggests it retains central neurological signaling without triggering systemic corticosteroid release. It is intended strictly for in vitro laboratory experimentation.
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, modified for metabolic stability. Research suggests it retains central neurological signaling without triggering systemic corticosteroid release. It is intended strictly for in vitro laboratory experimentation.
Standard Semax and N-Acetyl Semax differ by an acetyl modification on N-Acetyl Semax. Research suggests this chemical alteration influences the peptide’s metabolic stability and clearance profile, depending on the chosen experimental route and study design.
No standardized administration protocol exists outside individual study designs. Experimental routes, doses, and frequencies must be determined solely by qualified researchers in controlled institutional environments. Bodily administration to humans or animals is strictly prohibited by law.
While used clinically in Russia, Semax is not FDA-approved in the United States and is classified strictly as a research chemical. Preclinical and clinical literature reports general tolerability, but long-term safety evidence remains limited in Western trials.

REGULATORY DISCLAIMER · PEPTIDES

These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.

CellGenic ships exclusively to Mexico, Argentina, Colombia, and Perú under local license. Verified-provider-only platform from CellGenic.

Shopping cart0
There are no products in the cart!
Continue shopping
Cart Gated

Cart is provider-gated. Log in to view.

Provider Login →